Summary of Significant Accounting Policies - Segments (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($) segment	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Segments
Number of reportable segment | segment	1
Revenue	$ 69,300	$ 58,453	$ 41,418
Cost of revenue (excluding amortization of intangible assets)	22,432	17,961	13,570
Amortization of intangible assets	380	380	804
Gross profit	46,488	40,112	27,044
Sales and marketing:
Selling and Marketing Expense, Total	64,648	59,681	43,252
General and Administrative:
General and Administrative Expense, Total	14,722	14,887	13,862
Research and Development:
Research and Development Expense, Total	8,813	9,619	8,937
Gain on sale of product line	7,580
Net loss	(37,841)	(46,664)	(44,296)
Single reportable segment
Segments
Revenue	69,300	58,453	41,418
Cost of revenue (excluding amortization of intangible assets)	22,432	17,961	13,570
Amortization of intangible assets	380	380	804
Gross profit	46,488	40,112	27,044
Sales and marketing:
Sales and sales management	44,132	35,469	13,657
International	5,072	3,916	1,191
Other sales and marketing	15,444	20,296	28,404
Selling and Marketing Expense, Total	64,648	59,681	43,252
General and Administrative:
Finance and Legal	7,503	7,715	6,461
Other General and administrative	7,219	7,172	7,401
General and Administrative Expense, Total	14,722	14,887	13,862
Research and Development:
Clinical	4,068	3,891	1,064
Regulatory and quality	1,452	2,189	1,493
Other research and development	3,293	3,539	6,380
Research and Development Expense, Total	8,813	9,619	8,937
Other segment items	(3,726)	(2,589)	(5,289)
Gain on sale of product line	7,580
Net loss	$ (37,841)	$ (46,664)	$ (44,296)